| Literature DB >> 34305589 |
Saranya Nallusamy1, Jayakanthan Mannu1, Caroline Ravikumar1, Kandavelmani Angamuthu1, Bharathi Nathan1, Kumaravadivel Nachimuthu1, Gnanam Ramasamy1, Raveendran Muthurajan2, Mohankumar Subbarayalu3, Kumar Neelakandan4.
Abstract
Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) being a causative agent for global pandemic disease nCOVID'19, has acquired much scientific attention for the development of effective vaccines and drugs. Several attempts have been made to explore repurposing existing drugs known for their anti-viral activities, and test the traditional herbal medicines known for their health benefiting and immune-boosting activity against SARS-CoV-2. In this study, efforts were made to examine the potential of 605 phytochemicals from 37 plant species (of which 14 plants were endemic to India) and 139 antiviral molecules (Pubchem and Drug bank) in inhibiting SARS-CoV-2 multiple protein targets through a virtual screening approach. Results of our experiments revealed that SARS-CoV-2 MPro shared significant disimilarities against SARS-CoV MPro and MERS-CoV MPro indicating the need for discovering novel drugs. This study has screened the phytochemical cyanin (Zingiber officinale) which may exhibit broad-spectrum inhibitory activity against main proteases of SARS-CoV-2, SARS-CoV and MERS-CoV with binding energies of (-) 8.3 kcal/mol (-) 8.2 kcal/mol and (-) 7.7 kcal/mol respectively. Amentoflavone, agathisflavone, catechin-7-o-gallate and chlorogenin were shown to exhibit multi-target inhibitory activity. Further, Mangifera indica, Anacardium occidentale, Vitex negundo, Solanum nigrum, Pedalium murex, Terminalia chebula, Azadirachta indica, Cissus quadrangularis, Clerodendrum serratum and Ocimum basilicumaree reported as potential sources of phytochemicals for combating nCOVID'19. More interestingly, this study has highlighted the anti-viral properties of the traditional herbal formulation "Kabasura kudineer" recommended by AYUSH, a unit of Government of India. Short listed phytochemicals could be used as leads for future drug design and development. Genomic analysis of identified herbal plants will help in unraveling molecular complexity of therapeutic and anti-viral properties which proffer lot of chance in the pharmaceutical field for researchers to scout new drugs in drug discovery.Entities:
Keywords: SARS-CoV-2; agathisflavone; amentoflavone; cyanin; molecular docking; nCOVID-19
Year: 2021 PMID: 34305589 PMCID: PMC8295902 DOI: 10.3389/fphar.2021.667704
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Protein targets with their PDB ID and the binding site volume.
| S. No | PDB ID | Protein name | Binding site volume (Å) units |
|---|---|---|---|
| 1 | 2GZ9 | SARS-CoV MPro | 328.045 |
| 2 | 5C3N | MERS-CoV MPro | 317.710 |
| 3 | 5R81 | SARS-CoV2 MPro | 308.363 |
| 4 | 6M0J | Spike glycoprotein | 8,071.179 (interface of ACE and spike protein) |
| 5 | 6M71 | RNA-dependent RNA polymerase | 4,977.808 |
| 6 | 6W4H | NSP16 - NSP10 | 316.761 |
| 7 | 6W02 | NSP3 | 242.332 |
| 8 | 6W01 | NSP15 | 212.386 |
| 9 | 6W4B | NSP9 | 121.103 |
List of herbal plants used in the study for screening antiviral compounds and their distribution and medicinal uses.
| S. No | Plant name/Tamil name | Geographical distribution of plants | Plant part | Medicinal use | References |
|---|---|---|---|---|---|
| 1. |
| Native to tropic and subtropical regions, found in Karnataka and Tamil nadu | Root, flower, leaf | Anti-oxidant, anti-bacterial, analgesic, anti-inflammatory, anti-cancer, hepato-protective, immuno-modulatory and larvicidal activities |
|
| 2. |
| Throughout asia | Leaves and rhizome | Anti-oxidant, anti-inflammatory, anti-ulcer, anti-diabetic, anti-microbial, wound-healing, antiraioprotective, pesticidal and insecticidal properties |
|
| 3. |
| Indian sub continent and southeast asia | Leaves and fruits | Antidiabetic, anticancerous, antifertility, antimicrobial, immunogenic, and insecticidal activities |
|
| 4. |
| Native to mediterranean europe and parts of north africa, but also naturalized in other parts of europe, India and Pakistan | Root | Antidiabetic, sialagogue, aphrodisiac, immunostimulant, antidepressant, antimicrobial, insecticide, anesthetic, anti-inflammatory Anticonvulsant, antioxidant |
|
| 5. |
| Native to India and Sri Lanka | Plant | Anticancer, antidiarrheal, antihepatitis, anti-hiv, antihyperglycemic, anti-inflammatory, antimicrobial, antimalarial, antioxidant, cardiovascular, cytotoxic, hepatoprotective, immunostimulatory, and sexual dysfunctions |
|
| 6. |
| Indian sub continent and throughout south asia | Leaves | Anti-inflammatory, antiarthritic, antipyretic, hypoglycemic, antigastric ulcer, antifungal, antibacterial, and antitumour activities |
|
| 7. |
| Originated from europe and distributed in caribean countries, Indonesia, Malaysia and India | Root, shoot, stem, leaves, leaf buds, flower buds, florets, landraces, sprouts, inflorescence, seeds, seed oil, and callus | Antimicrobial, antibacterial, antidiabetic, antimalarial, antiaging, antiulcer, anti-hyperglycemic, anti-hyperlipidemic, anti-proliferative, neuroprotective, antidiabetic, anti-genotoxic and antioxidant activities |
|
| 8. |
| Originated from mesoamerica and distributed in other tropical and subtropical regions of the world | Leaves, root, fruit, seeds | Antiparasitic, antiseptic, antiparasitic, antimicrobial, antiinflammatory, antihyperlipidemic, antihypertensive and antidiabetic |
|
| 9. |
| India, Bangladesh and Srilanka | Stem | Anti-ulcer, anti-bacterial, anxiolytic, antipyretic, antidiabetic, bone healing, antioxidant and anti-inflammatory properties |
|
| 10. |
| Bengal, Odisha and Peninsular India | Plant, root and leaves |
|
|
| 11. |
| South East Asia | Leaves, root, coconut oil, shell, fruit | Antihelminthic, anti-inflammatory, antinociceptive, antioxidant, antifungal, antimicrobial, and antitumor activities |
|
| 12. |
| Wetern Asia and Southern Europe | Fruits, leaves, plant | Antibacterial, antifungal and anti-oxidative activities |
|
| 13. |
| Indan subcontinent and South East Asia | Root | Anti-infammatory, antioxidant, antimutagenic, antidiabetic, antibacterial, hepatoprotective, expectorant and anticancerous |
|
| 14. |
| Southern Asia, Africa, Southern and Central Europe | Root, rhizome, essential oil and tuber | Antiandrogenic, antibacterial, anticancerous, anticonvulsant, antidiabetic, antidiarrheal, antigenotoxic, anti-inflammatory, antilipidemic, antimalarial, antimutagenic, antiobesity, antioxidant, anti-uropathogenic, hepatoprotective, cardioprotective, neuroprotective, and nootropic agent |
|
| 15. |
| Western Asia, Northern Africa and Eurasia | Liquorice extract, root | Antibacterial, antioxidant, antimalarial, antispasmodic, antiinflammatory and anti-hyper glycemic antiulcer, antiviral, anti-hepatotoxic, antifungal properties |
|
| 16. |
| Tropical asi and africa | Root, stem | Anti-nociceptive, antitumor, antioxidant, hepatoprotective, hypoglycemic, hematinic, diuretic, free radical scavenging, anthelmintic, anti-inflammatory, antipyretic, anabolic and androgenic activities | ( |
| 17. |
| South America and found in Tamil nadu | Plant extract | Glycosidase inhibitory activities, antioxidant antiinflammatory, antidiabetic, wound healing antimicrobial, immunomodulatory, cardiovascular, abortifacient, antifungal, anticancer and hepatoprotective | (Saxena, Tyagi, kumar, singh) |
| 18. |
| Asia | Plant, flower, leaf | Antitussive, abortifacient, antimicrobial, cardiovascular protection, anticholinesterase, antiinflammatory |
|
| 19. |
| Central Asia and Europe and cultivated world wide | Fruit | Antioxidant, antiproliferative, anti-depressant, antiinflammatory, anti-microbial |
|
| 20. |
| Southwest Asia, Southern Europe, North Africa | Seed | Antidiabetic, anticancer, immunomodulator, analgesic, antimicrobial, anti-inflammatory, spasmolytic, bronchodilator, hepato-protective, renal protective, gastro-protective, antioxidant properties |
|
| 21. |
| South East Asia and Central Africa | Leaves | Anti-cancer, radioprotective, anti-microbial, anti-inflammatory effects, immunomodulatory, anti-stress, anti-diabetic, anti-pyretic, anti-arthritic, anti-oxidant, as a prophylactic agent and in cardiovascular disease |
|
| 22. |
| India and South East Asia | Leaves, stem, flower, root, seeds and even whole plant | Antifertility, anticancer, antidiabetic, antifungal, antimicrobial, hepatoprotective, cardioprotective, antiemetic, antispasmodic, analgesic, adaptogenic and diaphoretic actions |
|
| 23. |
| Southern part and deccan region of India and Ceylon | Whole plant, root, seed, leaf | Antiulcerogenic, nephroprotective, hypolipidemic, aphrodisiac, antioxidant, antimicrobial and insecticidal activities |
|
| 24. |
| South asia (India, southern Thailand, Malaysia) | Fruit, seed, seed essential oil | Antihypertensive and antiplatelets, antioxidant, antitumor, antiasthmatics, antipyretic, analgesic, anti-inflammatory, anti-diarrheal, antispasmodic, anxiolytic, antidepressants, hepato-protective, immuno-modulatory, antibacterial, antifungal, anti-thyroids, antiapoptotic, anti-metastatic, antimutagenic, anti-spermatogenic, anticolon toxin, insecticidal and larvicidal activities |
|
| 25. |
| India tropical and coastal areas | Leaves, whole plant | Antiviral, antibacterial, antiplasmodial, anti-inflammatory, antimalarial, antimicrobial, anticancer, antidiabetic, hypolipidemic, antioxidant, hepatoprotective nephroprotective and diurectic properties |
|
| 26. |
| Cultivated in India, srilanka, Malaysia, Thailand, Taiwan and southeast asian countries | Leaves | Antimicrobial, gastroprotective, wound healing, hepatoprotective, antioxidant, anti-fertility on male rats, and antimotility effects on washed human spermatozoa |
|
| 27. |
| South Asia | Flower, root | Anti-diabetic and anti-hyperlipidemic, hepatoprotective, neuroprotective, cardioprotective, anti-bacterial, aphrodiasiac, relieves respiratory disorders |
|
| 28. |
| India, Sri Lanka | Leaves | Antimicrobial, antifungal, anti-inflammatory, antidiabetic, anxiolytic, antineoplastic, analgesic, antimalarial, antibiofilm efficacy, diuretic, wound healing, skincare, respiratory disorders, and antiplatelet aggregation |
|
| 29. |
| Middle east and naturalized throughout the world | Leaf | Anticancer, anti-inflammatory, antinociceptive, antioxidant, antimicrobial, antimutagenic, antidementia, hypoglycemic, and hypolipidemic effects |
|
| 30. |
| Eurasia | Leaves | Anti-oxidant, anti-cancer |
|
| 31. |
| India | Fruit, leaves | Antihypertensive, antioxidant, cardiovascular, anti-platelet aggregation activities, anti-microbial, sedative, digestive, hemostatics and diuretic activities |
|
| 32. |
| Southern India | Leaf, stem, root, flowers and berries | Anti-microbial, anti-inflammatory, antioxidant, cytotoxic, anti-diabetic and immunomodulatory activities |
|
| 33. |
| Maluku islands (or moluccas) in Indonesia and available throughout the year owing to different harvest seasons in different countries | Flower | Analgesic, antioxidant, anticancer, antiseptic, anti-depressant, antispasmodic, anti-inflammatory, antiviral, antifungal, and antibacterial |
|
| 34. |
| Southeast Asia | Fruit | Antisecretory, analgesic, antihypertensive, antidiarrhoeal, antimicrobial antidiabetic, antioxidant, antiulcer, antipyretic, hepatoprotective, anticancer, angiogenesis, antidepressant-like and anti-urolithiatic |
|
| 35. |
| South asia from India and Nepal | Fruit | Antibacterial, antifungal, antiviral, antidiabetic, antimutagenic, antioxidant, antiulcer and wound healing |
|
| 36. |
| Asia, southern and Eastern africa | Leaves | Analgesic, anti-inflammatory, antimicrobial, antioxidant, hepatoprotective, antihistamine, and antiasthmatic |
|
| 37. |
| Maritime Southeast Asia | Rhizome | Cardioprotective, antiinflammatory, antimicrobial, antioxidant, antiulcer, anticlotting and anticancer |
|
Kabasura kudineer-plant compounds.
FIGURE 1Multiple sequence alignment of SARS-CoV-2 (PDB ID: 5R81), SARS-CoV (PDB ID: 2GZ9) and MERS-CoV (PDB ID: 5C3N) main proteases. Binding site residues are marked with blue box. Red marked residues indicate the change observed between SARS-CoV-2 and SARS CoV. * denotes the conserved regions with identical residues. Serine to Alanine change at the 45th position observed in the binding site is marked with circle.
FIGURE 2Phylogenetic analysis of SARS-CoV-2MPRO with other CoV MPRO proteins.
Binding site residues of CoV protein targets used for virtual screening.
| Protein name | Binding site residues |
|---|---|
| Main protease (SARS-CoV) | 25 THR, 26 THR, 27 LEU, 41 HIS, 44 CYS, 45 THR, 46 ALA, 49 MET, 140 PHE, 141 LEU, 142 ASN, 143 GLY, 144 SER, 145 CYS, 163 HIS, 164 HIS, 165 MET, 166 GLU, 167 LEU, 168, PRO, 172 HIS, 188 ARG, 189 GLN, 190 THR, 192 GLN |
| Main protease (MERS-CoV) | 1 SER, 25 MET, 26 THR, 27 LEU, 41 HIS, 42 VAL, 44 CYS, 46 ALA, 49 LEU, 143 PHE, 144 LEU, 145 CYS, 146 GLY, 148 CYS, 166 HIS, 167 GLN, 168 MET, 169 GLU, 170 LEU, 171 ALA, 175 HIS, 190 ASP, 191 LYS, 192 GLN, 193 VAL, 194 HIS, 195 GLN, 196 VAL |
| Main protease (SARS-CoV-2) | 24 THR, 25 THR, 26 THR, 27 LEU, 41 HIS, 44 CYS, 45 THR, 46 SER, 49 MET, 140 PHE, 141 LEU, 142 ASN, 143 GLY, 144 SER, 145 CYS, 163 HIS, 164 HIS, 165 MET, 166 GLU, 167 LEU, 168 PRO, 187 ASP, 188 ARG, 189 GLN, 190THR, 192 GLN |
| Spike glycoprotein |
|
| RNA-dependent RNA polymerase NSP 12 | 164 ASP, 166 VAL, 167 GLU, 429 PHE, 430 LYS, 431 GLU, 436 GLU, 437 LEU, 438 LYS, 439 HIS, 440 PHE, 441 PHE, 442 PHE, 452 ASP, 455 TYR, 456 TYR, 494 ILE, 496 ASN, 497 ASN, 499 ASP, 500 LYS, 66,501 SER, 503 GLY, 507 ASN, 511 LYS, 540 THR, 541 GLN, 542 MET, 543 ASN, 544 LEU, 545 LYS, 546 TYR, 547 ALA, 548 ILE, 549 SER, 550 ALA, 551 LYS, 553 ARG, 554 ALA, 555 ARG, 556 THR, 557 VAL, 558 ALA, 559 GLY, 565 THR, 568 ASN, 569 ARG, 572 HIS, 573 GLN, 576 LEU, 577 LYS, 580 ALA, 588 VAL, 589 ILE, 590 GLY, 591 THR, 592 SER, 593 LYS, 594 PHE, 598 TRP, 601 MET, 602 LEU, 616 GLY, 617 TRP, 618 ASP, 619 TYR, 620 PRO, 621 LYS, 622 CYS, 623 ASP, 624 ARG, 665 GLU, 667 VAL, 676 LYS, 680 THR, 681 SER, 682 SER, 683 GLY, 684 ASP, 685 ALA, 686 THR, 687 THR, 688 ALA, 689 TYR, 691 ASN, 756 MET, 758 LEU, 759 SER, 760 ASP, 761 ASP, 762 ALA, 763 VAL, 792 VAL, 793 PHE, 795 SER, 797 ALA, 798 LYS, 799 CYS, 800 TRP, 810 HIS, 811 GLU, 812 PHE, 813 CYS, 814 SER, 815 GLN, 816 HIS, 833 ASP, 835 SER, 836 ARG, 837 ILE, 840 ALA, 841 GLY, 843 PHE, 844 VAL, 845 ASP, 847 ILE, 848 VAL, 854 LEU, 855 MET, 857 GLU, 858 ARG, 859 PHE, 861 SER, 862 LEU, 864 ILE, 865 ASP |
| NSP16 - NSP10 | 6841 ASN, 6844 LYS, 6845 TYR, 6867HIS, 6868PHE, 6869 GLY, 6870ALA, 6871GLY, 6872SER, 6873ASP, 6878PRO, 6879 GLY, 6896SER, 6897ASP, 6898LEU, 6899ASN, 6900 ASP, 6901PHE, 6911GLY, 6912ASP, 6913CYS, 6928ASP, 6929 MET, 6930 TYR, 6931 ASP, 6932 PRO, 6933LYS, 6947 PHE, 6968 LYS |
| NSP3 | 6 PHE, 7 SER, 8 GLY, 10 LEU, 11 LYS, 12 LEU, 18 ILE, 19 LYS, 20 ASN, 158 LYS, 161 TYR, 162 ASP, 165 VAL, 168 PHE |
| NSP15 | 69 GLU, 71 LYS, 90 LYS, 196 THR, 198 SER, 199 ARG, 200 ASN, 201 LEU, 202 GLN, 252 LEU, 255 LEU, 259 PHE, 266LEU, 268 ASP, 272 MET, 273 ASP. 274 SER, 275 THR, 277 LYS, 279 TYR, 295 VAL, 296 ILE, 297 ASP |
| NSP9 | 13 MET, 33 TYR, 38 GLY, 39 GLY, 40 ARG, 42 VAL, 57PHE, 58 PRO, 59 LYS, 60 SER, 66 ILE, 68 THR |
Binding affinity value of Hydroxychloroquine, Cholroquine and Ivermectin against SARS-COV-2 targets.
| SARS-CoV-2Protein target | Hydroxychloroquine (pubchem ID: 3652) binding affinity (kcal/mol) | Chloroquine (pubchem ID: 2719). Binding affinity (kcal/mol) | Ivermectin (pubchem ID: 6427057). Binding affinity (kcal/mol) |
|---|---|---|---|
| SARS-CoV-2MPro | −5.5 | −4.9 | −7.3 |
| RdRp | −5.6 | −5.4 | −9.4 |
| NSP3 | −4.5 | −4.2 | −6.7 |
| NSP9 | −5.7 | −5.2 | −7.5 |
| NSP16 - NSP10 | −5.7 | −5.3 | −1.9 |
| NSP15 | −5.5 | −5.4 | −6.4 |
| Spike glycoprotein | −5.3 | −5.2 | −8.2 |
Details of shortlisted top 10 natural compounds/small molecules screened against various targets of coronaviruses.
| Protein name | Binding affinity kcal/mol | Compound name | Puchem ID | Chemical structure | Bioavailability score | Solubility score/Class | Plant name |
|---|---|---|---|---|---|---|---|
| SARS COV main protease (PDB ID: 2GZ9) | −9.0 | Rutin (ZINC4096846) | 5,280,805 |
| 0.17 | 0.29/Soluble |
|
| −8.7 | Quercetin 3 gentiobioside (ZINC49783852) | 5,320,834 |
| 0.17 | 0.29/Soluble |
| |
| −8.6 | 3-O-trans-caffeoyltormentic acid | 44,584,640 |
| 0.56 | -5.99/moderately soluble | Antiviral compounds | |
| −8.5 | (-)Epicatechin 3 o gallate (epicatechin) | 107,905 |
| 0.55 | -3.09/soluble |
| |
| −8.5 | Corilagin ( | 73,568 |
| 0.17 | -0.51/soluble |
| |
| −8.4 | Quercetin galactoside ( | 5,281,643 |
| 0.17 | -1.51/soluble | Antiviral compounds | |
| −8.3 | Quercetrin ( | 5,280,459 |
| 0.17 | -2.08/soluble |
| |
| −8.3 | Isoquercetin (ZINC4096845) | 5,280,804 |
| 0.17 | -1.51/soluble |
| |
| −8.3 | Acetoside (ZINC8234351) | 5,281,800 |
| 0.17 | -0.22/soluble |
| |
| −8.2 | Cyanin (ZINC4097727) | 441,688 |
| 0.17 | 0.86/soluble |
| |
| SARS-COV-2 main protease (PDB ID: 5R81) | −8.2 | Agathisflavone ( | 5,281,599 |
| 0.17 | -8.7/Poorly soluble |
|
| −8.1 | Rubusic acid | 101,297,651 |
| 0.56 | -5.3/moderately soluble |
| |
| −7.9 | Solanocapsine | 73,419 |
| 0.55 | -4.2/moderately soluble |
| |
| −7.7 | Chlorogenin (ZINC84668707) | 12,303,065 |
| 0.55 | -3.69/soluble |
| |
| −7.7 | Lupeol ( | 259,846 |
| 0.55 | -6.74/poorly soluble |
| |
| −7.7 | Cyanin (ZINC4097727) | 441,688 |
| 0.17 | 0.86/soluble |
| |
| −7.7 | 3-O-trans-caffeoyltormentic acid | 44,584,640 |
| 0.56 | -5.99/moderately soluble | Antiviral compound | |
| −7.7 |
| 5,281,669 |
| 0.11 | -2.05/soluble |
| |
| −7.6 | Agnuside ( | 442,416 |
| 0.17 | 0.66/soluble |
| |
| −7.6 | Luteolin 7-O-beta-D-glucoside ( | 5,280,637 |
| 0.17 | -2.1/soluble |
| |
| MERS main protease (MERS) (PDB ID: 5C3N) | −8.6 | Amentoflavone ( | 5,281,600 |
| 0.17 | -8./poorly soluble |
|
| −8.4 | Corilagin ( | 73,568 |
| 0.17 | -0.51/soluble |
| |
| −8.3 | Cyanin (ZINC4097727) | 441,688 |
| 0.17 | 0.86/soluble |
| |
| −8.2 | Rutin ( | 5,280,805 |
| 0.17 | -0.29/soluble |
| |
| −8.2 | Betulinic acid ( | 64,971 |
| 0.85 | -5.7/moderately soluble |
| |
| −8.1 | 3.8'-biapigenin ( | 10,414,856 |
| 0.17 | -8.7/poorly soluble |
| |
| −8.0 | (-)-Epicatechin-3-o-gallate ( | 107,905 |
| 0.55 | -3.09/soluble |
| |
| −8.0 | Chrysanthemin ( | 441,667 |
| 0.17 | -0.93/soluble |
| |
| −8.0 | Vicenin-2 ( | 442,664 |
| 0.17 | -0.27/soluble |
| |
| −8.0 | Quercetin 3 gentiobioside ( | 5,320,834 |
| 0.17 | 0.29/soluble |
| |
| RNA-dependent RNA polymerase (PDB ID: 6M71) | −9.4 | Ivermectin ( | 6,427,057 |
| 0.17 | -3.89/soluble | FDA approved drug |
| −9.3 | Amentoflavone ( | 5,281,600 |
| 0.17 | -8.7/poorly soluble |
| |
| −9.0 | Corilagin ( | 73,568 |
| 0.17 | -0.51/soluble |
| |
| −8.9 | Agathisflavone ( | 5,281,599 |
| 0.17 | -8.7/poorly soluble |
| |
| −8.6 | 3-O-trans-caffeoyltormentic acid | 44,584,640 |
| 0.56 | -5.99/moderately soluble | Antiviral compound | |
| −8.2 | Arjungenin ( | 6,321,424 |
| 0.17 | -3.89/soluble |
| |
| −8.2 | Crateogolic acid ( | 12,444,386 |
| 0.56 | -3.9/soluble |
| |
| −8.1 | Maslinic acid ( | 73,659 |
| 0.56 | -5.3/moderately soluble | Antiviral compound | |
| −8.0 | 3.8'-biapigenin (ZINC17545,581)) | 10,414,856 |
| 0.17 | -8.7/Poorly soluble |
| |
| −7.9 | Cyanin | 441,688 |
| 0.17 | 0.86/soluble |
| |
| NSP9 (PDB ID: 6W4B) | −9.6 | Friedelin ( | 91,472 |
| 0.55 | -7.88/poorly soluble |
|
| −9.3 | N-methylsolasodine | 21,573,751 |
| 0.55 | -4.46/moderately soluble |
| |
| −8.9 | Solasodine ( | 442,985 |
| 0.55 | -4.8/moderately soluble |
| |
| −8.9 | Diosgenin ( | 99,474 |
| 0.55 | -4.49/moderately soluble |
| |
| −8.6 | Spirostan-3-ol (ZINC253504500) | 3,035,446 |
| 0.55 | -4.51/Moderately soluble |
| |
| −8.6 | Solanocapsine | 73,419 |
| 0.55 | -4.22/moderately soluble |
| |
| −8.5 | Taraxerol (ZINC4082498) | 92,097 |
| 0.55 | -7.16/Poorly soluble |
| |
| −8.3 | Amentoflavone ( | 5,281,600 |
| 0.17 | -8.7/Poorly soluble |
| |
| −8.2 | Chlorogenin (ZINC84668707) | 12,303,065 |
| 0.55 | -3.69/soluble |
| |
| −8.1 | Agathisflavone ( | 5,281,599 |
| 0.17 | -8.7/poorly soluble |
| |
| NSP15 (PDB ID: 6W01) | −9.2 | Oleanolic acid ( | 10,494 |
| 0.85 | -6.12/poorly soluble |
|
| −9.2 | Ursolic-acid ( | 64,945 |
| 0.85 | -5.67/moderately soluble |
| |
| −8.9 | Crategolic acid ( | 73,659 |
| 0.56 | -5.3/Moderately soluble |
| |
| −8.8 | Arjungenin ( | 12,444,386 |
| 0.56 | -3.9/soluble |
| |
| −8.7 | Hederagenin ( | 73,299 |
| 0.56 | -5.55/moderately soluble |
| |
| −8.6 | Triterpenoid (ZINC40164454) | 451,674 |
| 0.56 | -5.12/moderately solule |
| |
| −8.6 | Beta-amyrin ( | 73,145 |
| 0.55 | -7.16/poorly solube |
| |
| −8.6 | Friedelin ( | 91,472 |
| 0.55 | -7.88/poorly soluble |
| |
| −8.5 | Catechin 7-O-gallate | 471,393 |
| 0.55 | -3.09/soluble |
| |
| −8.5 | Arjunolic acid ( | 73,641 |
| 0.56 | -4.72/moderately soluble |
| |
| NSP3 (PDB ID: 6W02) | −7.4 | Amentoflavone ( | 5,281,600 |
| 0.17 | -8.7/poorly soluble |
|
| −7.1 | Luteolin 7-O-(6''-malonylglucoside) | 5,281,669 |
| 0.11 | -2.05/soluble |
| |
| −6.8 | Rubusic acid | 101,297,651 |
| 0.56 | -5.3/moderately soluble |
| |
| −6.7 | Acteoside ( | 5,281,800 |
| 0.17 | -0.22/soluble |
| |
| −6.7 | Ivermectin ( | 6,427,057 |
| 0.17 | -3.89/soluble | FDA approved drug | |
| −6.7 | Taraxerol acetate ( | 94,225 |
| 0.55 | -7.77/poorly soluble |
| |
| −6.6 | Catechin 7-O-gallate | 471,393 |
| 0.55 | -3.09/soluble | Antiviral compound | |
| −6.6 | Luteolin 7-O-beta-D-glucoside ( | 5,280,637 |
| 0.17 | -2.1/soluble |
| |
| −6.6 | Agathisflavone ( | 5,281,599 |
| 0.17 | -8.7/poorly soluble |
| |
| −6.6 | Luteolin-7-o-beta-d-glucopyranoside | 5,291,488 |
| 0.17 | -2.1/soluble |
| |
| NSP10-NSP16 (PDB ID: 6W4H) | −8.5 | Amentoflavone ( | 5,281,600 |
| 0.17 | -8.7/poorly solbule |
|
| −8.3 | 10-Methoxycamptothecin ( | 97,283 |
| 0.55 | -5.93/moderately soluble | Antiviral compound | |
| −8.2 | 3.8'-biapigenin ( | 10,414,856 |
| 0.17 | -8.7/poorly soluble | Antiviral compound | |
| −8.0 | Taraxerol acetate ( | 94,225 |
| 0.55 | -7.77/poorly soluble |
| |
| −7.8 | Corilagin ( | 73,568 |
| 0.17 | -0.15/soluble |
| |
| −7.8 | Lupeol acetate ( | 92,157 |
| 0.55 | -7.35/poorly soluble |
| |
| −7.6 | Emetine ( | 10,219 |
| 0.55 | -7.7/poorly soluble | FDA approved drug | |
| −7.6 | Chlorogenin (ZINC84668707) | 12,303,065 |
| 0.55 | -3.69/soluble |
| |
| −7.6 | Spirostan-3-ol (ZINC253504500) | 14,492,795 |
| 0.55 | -6.56/poorly soluble |
| |
| −7.6 | 5,7-Dihydroxy-4'-methoxy-8.3'-di-C-prenylflavanone | 3,035,446 |
| 0.55 | -4.51/moderately soluble |
| |
| Spike glycoprotein (PDB ID: 6M0J) | −8.2 | 1,8-Dichloro-9,10-diphenylanthracene-9,10-diol (ZINC5438671) | 320,066 |
| 0.55 | -10.45/insoluble |
|
| −8.2 | Agathisflavone ( | 5,281,599 |
| 0.17 | -8.7/poorly soluble |
| |
| −8.2 | Amentoflavone ( | 5,281,600 |
| 0.17 | -8.7/poorly soluble |
| |
| −8.2 | Ivermectin ( | 6,427,057 |
| 0.17 | -3.89/soluble | FDA approved drug | |
| −8.1 | 3 o caffeoyltormentic acid | 44,584,640 |
| 0.56 | -5.99/moderately soluble | Antiviral compound | |
| −7.5 | Agnuside ( | 442,416 |
| 0.17 | 0.66/soluble |
| |
| −7.4 | 1,8-Dichloro-9,10-diphenylanthracene-9,10-diol (ZINC5438671) | 320,066 |
| 0.55 | -10.45/insoluble |
| |
| −7.3 | Taraxerol ( | 92,097 |
| 0.55 | -7.16/poorly soluble |
| |
| −7.3 | Nimbinene | 44,715,635 |
| 0.55 | -5.66/moderately soluble | Antiviral compound | |
| −7.3 | β-amyrin ( | 92,156 |
| 0.55 | -7.77/poorly soluble |
|
FIGURE 3Complex structure of Cyanin with (A) SARS-CoV-2 MPro (PDB ID: 5R81) (B) SARS-CoV MPro (PDB ID: 2GZ9) (C) MERS-CoVMPro (PDB ID: 5C3N).
FIGURE 4Docked complex structures of spike protein with (A) ivermectin, (B) agasthisflavone, (C) amentoflavone, and RdRp with (D) ivermectin (E) agasthisflavone (F) amentoflavone.
FIGURE 5Docked complex structures of NSP3 protein with (A) ivermectin (B) agasthisflavone (C) amentoflavone, and NSP9 with (D) ivermectin (E) agasthisflavone (F) amentoflavone.
FIGURE 6(A) PDB ID: 6M0J - Residue interaction between ACE-2 (chain A) and spike glycoprotein (chain E). (B) PDB ID: 6W4H - Interface of NSP10-NSP16 complex.
FIGURE 7Spike protein (PDB ID: 6M0J) complex with 1,8-Dichloro-9,10-diphenylanthracene-9,10-diol (binding affinity: 8.2 kcal/mol).
Phytochemicals having strong interaction based on the top 10 hits screened for SARS-CoV-2targets.
| S. No | Compound name | Plant name | Protein targets |
|---|---|---|---|
| Acetoside |
| NSP3 | |
| Agathisflavone |
| SARS-CoV-2Mpro | |
| RdRp | |||
| NSP3 | |||
| Spike glycoprotein | |||
| Agnuside |
| SARS-CoV-2Mpro | |
| Spike glycoprotein | |||
| Amentoflavone |
| RdRp | |
| NSP9 | |||
| NSP3 | |||
| NSP10-NSP16 | |||
| Spike glycoprotein | |||
| Arjungenin |
| RdRp | |
| NSP15 | |||
| Arjunolic acid |
| NSP15 | |
| Beta-amyrin |
| NSP15, spike glycoprotein | |
| Catechin 7-O-gallate |
| RdRp | |
| NSP15 | |||
| NSP3 | |||
| Spike glycoprotein | |||
| Chlorogenin |
| SARS-CoV-2Mpro | |
| NSP9 | |||
| NSP10-NSP16 | |||
| Corilagin |
| RdRp | |
| NSP10-NSP16 | |||
| Crategolic acid |
| NSP15 | |
| RdRp | |||
| Cyanin |
| SARS-CoV-2Mpro | |
| RdRp | |||
| Diosgenin |
| NSP9 | |
| Emetine | FDA approved drug | NSP10-NSP16 | |
| Friedelin |
| NSP9 | |
| NSP15 | |||
| Hederagenin |
| NSP15 | |
| Ivermectin | FDA approved drug | RdRp | |
| NSP3 | |||
| Spike glycoprotein | |||
| Lupeol |
| SARS-CoV-2Mpro | |
| Lupeol acetate |
| NSP10-NSP16 | |
| Luteolin 7-O-(6''-malonylglucoside) |
| SARS-CoV-2Mpro | |
| NSP3 | |||
| Luteolin 7-O-beta-D-glucoside |
| SARS-CoV-2Mpro | |
| NSP3 | |||
| Luteolin-7-o-beta-d-glucopyranoside |
| NSP3 | |
| Nimbinene |
| Spike glycoprotein | |
| N-methylsolasodine |
| NSP9 | |
| Oleanolic acid |
| NSP15 | |
| Rubusic acid |
| SARS-CoV-2Mpro | |
| NSP3 | |||
| Solanocapsine |
| SARS-CoV-2Mpro | |
| NSP9 | |||
| Solasodine |
| NSP9 | |
| Spirostan-3-ol |
| NSP9 | |
| NSP10-NSP16 | |||
| Taraxerol |
| NSP9 | |
| Spike glycoprotein | |||
| Taraxerol acetate |
| NSP3 | |
| NSP10-NSP16 | |||
| Triterpenoid |
| NSP15 | |
| Ursolic-acid |
| NSP15 | |
| 5,7-Dihydroxy-4'-methoxy-8.3'-di-C-prenylflavanone |
| NSP10-NSP16 | |
| 1,8-Dichloro-9,10-diphenylanthracene-9,10-diol |
| Spike glycoprotein | |
| 3 O caffeoyltormentic acid | Antiviral compound | Spike glycoprotein | |
| 10-Methoxycamptothecin | Antiviral compound | NSP10-NSP16 | |
| 3.8'-biapigenin | Antiviral compounds | RdRp | |
| NSP10-NSP16 | |||
| 3-O-trans-caffeoyltormentic acid | Antiviral compound | SARSCoV-2 Mpro | |
| RdRp |
Kabasura kudineer-plant compounds.
FIGURE 8Network diagram showing the interaction of plant phytochemcials with SARS-CoV-2 protein targets. Degree of connectivity represents number of SARS-CoV-2 that may be inhibited by each plant. In this network, NSP 15 stands first in the order where many plants connected (degree of connectivity) which indicates that metabolites from the connected plants has shown highest binding affinity (top ten screened compounds). Likewise, Vitex negundo was predicted to inhibit highest number of SARS-CoV-2 targets in the virtual screening. Plants name with * indicates their presence in Kabasura kudineer.